is present in high concentrations in human skeletal muscles. The oral ingestion of ␤-alanine, the rate-limiting precursor in carnosine synthesis, has been shown to elevate the muscle carnosine content both in trained and untrained humans. Little human data exist about the dynamics of the muscle carnosine content, its metabolic regulation, and its dependence on muscle fiber type. The present study aimed to investigate in three skeletal muscle types the supplementation-induced amplitude of carnosine synthesis and its subsequent elimination on cessation of supplementation (washout). Fifteen untrained males participated in a placebo-controlled doubleblind study. They were supplemented for 5-6 wk with either 4.8 g/day ␤-alanine or placebo. Muscle carnosine was quantified in soleus, tibialis anterior, and medial head of the gastrocnemius by proton magnetic resonance spectroscopy (MRS), before and after supplementation and 3 and 9 wk into washout. The ␤-alanine supplementation significantly increased the carnosine content in soleus by 39%, in tibialis by 27%, and in gastrocnemius by 23% and declined postsupplementation at a rate of 2-4%/wk. Average muscle carnosine remained increased compared with baseline at 3 wk of washout (only one-third of the supplementation-induced increase had disappeared) and returned to baseline values within 9 wk at group level. Following subdivision into high responders (ϩ55%) and low responders (ϩ15%), washout period was 15 and 6 wk, respectively. In the placebo group, carnosine remained relatively constant with variation coefficients of 9 -15% over a 3-mo period. It can be concluded that carnosine is a stable compound in human skeletal muscle, confirming the absence of carnosinase in myocytes. The present study shows that washout periods for crossover designs in supplementation studies for muscle metabolites may sometimes require months rather than weeks. ergogenic supplements; magnetic resonance spectroscopy; washout; carnosinase; skeletal muscle metabolism THE ROLE of the dipeptide carnosine (␤-alanyl-histidine) in skeletal muscle metabolism and contractile performance is receiving increased attention in the field of exercise physiology. This is related to the recent findings by Harris and coworkers (13, 14) showing that oral supplementation of ␤-alanine, the rate-limiting precursor in carnosine synthesis, can considerably elevate muscle carnosine content in humans. Importantly, the raised muscle carnosine content is associated with performance enhancement in exercise of short, intense nature (5, 14, 29) and in repeated maximal contraction bouts (6). There seems to be no positive effect of muscle carnosine loading on muscle strength (20), while the effect on isometric endurance is equivocal (6, 26). Other than that, relatively little is presently known about the ergogenic mechanism or the metabolic characteristics of carnosine in human skeletal muscle. It is hypothesized that carnosine acts as a proton buffer and protects the muscle from extreme acidosis during intense contractions (1, 4). Accordingly, across species (horse, camel, human) carnosine is highly abundant in fast-twitch muscle types (7, 8, 14) , which have the highest capacity to generate energy from anaerobic glycolytic metabolism.
The oral ingestion of ␤-alanine, the rate-limiting precursor in carnosine synthesis, has been shown to elevate the muscle carnosine content both in trained and untrained humans. Little human data exist about the dynamics of the muscle carnosine content, its metabolic regulation, and its dependence on muscle fiber type. The present study aimed to investigate in three skeletal muscle types the supplementation-induced amplitude of carnosine synthesis and its subsequent elimination on cessation of supplementation (washout). Fifteen untrained males participated in a placebo-controlled doubleblind study. They were supplemented for 5-6 wk with either 4.8 g/day ␤-alanine or placebo. Muscle carnosine was quantified in soleus, tibialis anterior, and medial head of the gastrocnemius by proton magnetic resonance spectroscopy (MRS), before and after supplementation and 3 and 9 wk into washout. The ␤-alanine supplementation significantly increased the carnosine content in soleus by 39%, in tibialis by 27%, and in gastrocnemius by 23% and declined postsupplementation at a rate of 2-4%/wk. Average muscle carnosine remained increased compared with baseline at 3 wk of washout (only one-third of the supplementation-induced increase had disappeared) and returned to baseline values within 9 wk at group level. Following subdivision into high responders (ϩ55%) and low responders (ϩ15%), washout period was 15 and 6 wk, respectively. In the placebo group, carnosine remained relatively constant with variation coefficients of 9 -15% over a 3-mo period. It can be concluded that carnosine is a stable compound in human skeletal muscle, confirming the absence of carnosinase in myocytes. The present study shows that washout periods for crossover designs in supplementation studies for muscle metabolites may sometimes require months rather than weeks. ergogenic supplements; magnetic resonance spectroscopy; washout; carnosinase; skeletal muscle metabolism THE ROLE of the dipeptide carnosine (␤-alanyl-histidine) in skeletal muscle metabolism and contractile performance is receiving increased attention in the field of exercise physiology. This is related to the recent findings by Harris and coworkers (13, 14) showing that oral supplementation of ␤-alanine, the rate-limiting precursor in carnosine synthesis, can considerably elevate muscle carnosine content in humans. Importantly, the raised muscle carnosine content is associated with performance enhancement in exercise of short, intense nature (5, 14, 29) and in repeated maximal contraction bouts (6) . There seems to be no positive effect of muscle carnosine loading on muscle strength (20) , while the effect on isometric endurance is equivocal (6, 26) . Other than that, relatively little is presently known about the ergogenic mechanism or the metabolic characteristics of carnosine in human skeletal muscle. It is hypothesized that carnosine acts as a proton buffer and protects the muscle from extreme acidosis during intense contractions (1, 4) . Accordingly, across species (horse, camel, human) carnosine is highly abundant in fast-twitch muscle types (7, 8, 14) , which have the highest capacity to generate energy from anaerobic glycolytic metabolism.
The present study is designed to explore the dynamics and stability of the muscle carnosine concentration in humans. It has been shown that ␤-alanine supplementation (4 -6 g/day for several weeks) can increase muscle carnosine content in humans by 20 -30% after 2 wk, by 40 -60% after 4 wk, and by 80% at week 10 (14, 19) . Thus, compared with muscle creatine loading, which is characterized by a maximal 30 -40% elevation within 1 wk (12), the carnosine loading is a considerably slower process, but with a higher magnitude. No data on the time course of muscle carnosine washout are currently available. This information would be valuable from a practical as well as a scientific point of view. In experimental supplementation studies a crossover design is preferable because the stronger within-subjects rather than between-subjects statistical comparison can be performed. In the 1990s, several studies identified that 4 wk following cessation of oral creatine supplementation muscle creatine content has returned to nearbaseline values (9, 16, 22, 33) . This 4 wk period is subsequently adopted as a suitable washout period for numerous crossover studies (28, 30) . An insight into the washout period of carnosine will favor future research on carnosine's ergogenic potential and metabolism. Additionally, ␤-alanine is becoming increasingly popular in athletes, who currently do not know how long effects are retained following cessation of supplementation.
Carnosine differs from creatine in its physiological mechanism of elimination from the muscle. For creatine a slow nonenzymatic and irreversible degradation into creatinine is constantly eliminating muscle creatine at a rate of 2% of the total creatine pool per day (34) . Carnosine, in contrast, is remarkably stable in solution in the absence of enzymes (10) . Carnosine and related dipeptides can be hydrolyzed by at least two types of dipeptidases that are members of a large family of metalloproteases (24, 31) . Serum carnosinase (CN1) is a secreted enzyme and is highly present and active in human plasma (17) . The latter explains the virtual absence of carnosine from human plasma in the postabsorptive state and the rapid and complete dipeptide hydrolysis within 3-4 h following an oral carnosine challenge (10) . A second enzyme, termed tissue carnosinase or nonspecific cytosolic dipeptidase (CN2), is widely expressed in human tissues, including brain (31) . The absence of carnosinase activity for several kinds of human and animal skeletal muscles was demonstrated by the Russian biochemist S. Severin (reviewed in Ref. 4 ) and others (11) . Also, Otani et al. (24) showed that mouse skeletal muscle expresses very little or no CN2. If carnosinases are absent from human muscle, then carnosine is hypothesized to remain stable in skeletal muscle and display a slow washout profile following ␤-alanine supplementation.
In the present study, we supplemented healthy young male subjects with ␤-alanine (4.8 g/day) for 5-6 wk and followed them 9 wk into the washout (postsupplementation) period. We measured muscle carnosine content by proton magnetic resonance spectroscopy ( 1 H-MRS), as previously described (6, 25) . This noninvasive approach allowed us to sample different muscles of the lower leg, i.e., soleus, tibialis anterior, and medial head of the gastrocnemius, of which the former has a predominant slow-twitch profile and the latter contains more fast-twitch fibers (18) . The general goal of the present study was to investigate the magnitude of carnosine loading and the time course of subsequent unloading in different human skeletal muscle types. We hypothesized that muscle carnosine washout is a relatively slow process.
MATERIALS AND METHODS
Subjects. Twenty male students volunteered to participate in this study. All subjects were physically active but not involved in regular training. The subjects' age and weight was 22.2 Ϯ 0.8 yr and 72.1 Ϯ 4.0 kg for the placebo group and 23 Ϯ 2.5 yr and 71.7 Ϯ 5.3 kg for the ␤-alanine group, respectively [not significant (NS)]. None of the subjects was taking any other oral supplement during the study or had taken supplements in the 3 mo before the study. The subjects gave their informed consent, and the study was approved by the local Ethics Committee (Ghent University Hospital, Ghent, Belgium). They also completed a questionnaire about their meat and fish consumption during 2 wk to quantify daily dietary ␤-alanine ingestion. Based on literature data, a table was composed with an overview of how much ␤-alanine (g/kg meat or fish) in the form of histidine-containing dipeptides (anserine, balenine, and carnosine) each type of meat or fish contains.
Study design. The subjects of this placebo-controlled, double-blind study were supplemented for 5-6 wk with either placebo (maltodextrine) or ␤-alanine (Carnosyn, National Alternatives International, San Marcos, CA). Supplements were provided in capsules of 400 mg and were administered each day as six divided doses, with at least 2 h in between ingestions. Daily doses consisted of 2.4 g/day during the first 2 days, 3.6 g/day during the subsequent 2 days, and from then on 4.8 g/day until the end of the supplementation. Carnosine quantification was performed in the week before the start of supplementation (Pre), during the last week of supplementation (Post), and 3 wk and 9 wk following the end of supplementation. The subjects were instructed not to exercise 24 h before each test. Of the 10 subjects that started in each group, 1 person of the experimental group dropped out during the supplementation period, 2 persons of the placebo group during the first washout, and a further 1 of each group during the second washout period, leaving us with a final number of 8 in the ␤-alanine group and 7 in the placebo group. No side effects were reported during the study.
Proton MRS. Carnosine content was measured in three skeletal muscles (%type I/II fibers: soleus, 86/14; tibialis anterior, 73/27; and gastrocnemius, 44/56; Ref. 18 ) of the lower leg by 1 H-MRS, as previously described (6, 25) . The subjects lied in supine position on their back and the lower leg was fixed in a holder with the angle of the ankle at 20°plantar flexion. All the MRS measurements were performed on a 3-T whole body MRI scanner (Siemens Trio, Erlangen, Germany) equipped with a knee coil. Single-voxel point-resolved spectroscopy with the following parameters was used: repetition time (TR) ϭ 2.000 ms; echo time (TE) ϭ 30 ms; number of excitations ϭ 128; 1,024 data points; spectral bandwidth of 1,200 Hz; and a total acquisition time of 4.24 min. The sequence was repeated without selective water suppression and eight acquisitions to use the water signal as an internal reference for carnosine quantification. The average voxel size of the soleus, tibialis anterior, and gastrocnemius was, respectively, 40 mm ϫ 14 mm ϫ 28 mm, 40 mm ϫ 16 mm ϫ 28 mm, and 40 mm ϫ 15 mm ϫ 30 mm. All voxel volumes ranged between 12.0 and 20.9 ml. Line width of the water signal was on average 25.8, 28.4, and 26.1 Hz during shimming for soleus, tibialis, and gastrocnemius, respectively. The integral of the C2-H peak (at ϳ8 ppm) was quantified relative to the water peak integral.
Statistics. A four ϫ two repeated-measures (RM) ANOVA was used to evaluate carnosine concentration of the three skeletal muscle types, with "group" (placebo vs. ␤-alanine) as between-subjects factor, and "time" (Pre, Post, washout 3 wk and washout 9 wk) as a within-subjects factor (SPSS Statistical Software, SPSS, Chicago, IL). In case of significant interaction, ANOVA was repeated on each group individually. Values are presented as means Ϯ SD, and significance was assumed at P Ͻ 0.05.
RESULTS
Muscle carnosine content. In the soleus muscle (Fig. 1A) , the absolute carnosine concentration before supplementation was 5.85 Ϯ 0.76 and 5.63 Ϯ 0.94 mM in the placebo and ␤-alanine groups, respectively. As a result of 5-6 wk of supplementation, the carnosine content in the soleus muscle increased by 39% (P ϭ 0.003) in the ␤-alanine group to 7.83 Ϯ 1.74 mM, whereas it remained stable at 5.89 Ϯ 0.91 mM (ϩ1.70% P ϭ 0.867) in the placebo group. The carnosine content of the tibialis anterior (Fig. 1B) increased from 6.25 Ϯ 1.11 to 7.93 Ϯ 1.70 mM in the ␤-alanine group (ϩ27% P ϭ 0.005) and decreased 17% from 5.51 Ϯ 0.62 to 4.55 Ϯ 1.25 mM (P ϭ 0.05) in the placebo group. Also in the gastrocnemius (Fig. 1C) , the carnosine content of the ␤-alanine group increased 23% (from 7.66 Ϯ 1.37 to 9.45 Ϯ 1.78 mM; P ϭ 0.038), whereas the carnosine concentration of the placebo group did not change (6.98 Ϯ 1.20 vs. 7.18 Ϯ 1.38 mM; P ϭ 0.740). The relative increase in carnosine content is significantly higher in the soleus than in the tibialis anterior (P ϭ 0.038) and the gastrocnemius (P ϭ 0.021).
The rate of carnosine elimination from the muscle on cessation of supplementation was measured after 3 and 9 wk. After a washout of 3 wk only 26.1% of the increase in the soleus (P ϭ 0.171) (compared with postsupplementation value), 20.1% of the increase in tibialis (P ϭ 0.50), and 44.7% of the increase in gastrocnemius (P ϭ 0.166) had disappeared. The absence of a difference (P ϭ 0.431) between the placebo and ␤-alanine group in carnosine concentration of the gastrocnemius 3 wk after cessation of supplementation was partly due to an increase in the placebo group. At that time the carnosine content of the gastrocnemius of the ␤-alanine group was not significantly different from the concentration before supplementation (P ϭ 0.072). For the three muscles together only 31.8% of the average increase in carnosine content had disappeared after a washout period of 3 wk. Nine weeks after cessation of supplementation, the carnosine content in the soleus (5.88 Ϯ 0.8 mM) was not different from the initial carnosine content (5.63 Ϯ 0.91 mM) (P ϭ 0.493) (Fig. 1A) .
The carnosine concentration of the tibialis anterior (P ϭ 0.751) and the gastrocnemius (P ϭ 0.990) returned also to their initial levels after a washout of 9 wk (Fig. 1, B and C) .
Additionally, we post hoc analyzed the washout profile in subjects of the ␤-alanine group that responded well to supplementation (high responders; Ͼ30% increase postsupplementation) and those that did not respond well (low responders; Ͻ30% increase postsupplementation). The results of this analysis on all muscles combined are shown in Fig. 2 . High responders (n ϭ 3) had an average 55% increase in muscle carnosine content postsupplementation and a washout rate of 3.5%/wk, indicating that it would take 14.6 wk for complete washout (based on linear regression; Fig. 2B ). Low responders (n ϭ 5) had an average 15% increase and a washout rate of 2.5%/wk, indicating that it would take 6.5 wk for complete washout. Similar values were observed for the different muscle types.
Dietary ␤-alanine intake. The subjects' daily average ␤-alanine ingestion by meat and fish consumption was 0.32 Ϯ 0.11 g for placebo and 0.30 Ϯ 0.10 g for the ␤-alanine group. There was no significant correlation between the baseline carnosine content (n ϭ 20) of the soleus (P ϭ 0.698), tibialis anterior (P ϭ 0.768), or gastrocnemius (P ϭ 0.787) and the daily average ␤-alanine ingestion by meat or fish consumption.
Coefficient of variation. The variation coefficient (CV ϭ SD/mean) of the carnosine concentration was calculated for each muscle in the placebo group over a time period of 15 wk. Table 1 shows that the soleus had a smaller variation (9.8%) than the tibialis (13.8%) and the gastrocnemius (14,2%).
DISCUSSION
A primary goal of the present study was to determine the rate of carnosine elimination from the muscle following a ␤-alanine supplementation-induced loading phase. The results clearly demonstrate that muscle carnosine unloading is a slow process. After 3 wk of washout only ϳ30% or 0.57 mM of the increase had disappeared from the muscle, whereas 9 wk postsupplementation the carnosine content had returned to baseline values. Figure 3 shows a comparison of the washout profile of carnosine with published data on creatine. It is clear that the unloading of (phospho)creatine is faster with a return to baseline in a little more than 4 wk. In absolute terms, the elimination of creatine is ϳ0.15 mM/day (22) , which is much higher than the 0.03 mM/day for carnosine. From this high stability of muscle carnosine, we can suggest several implications for carnosine metabolism. Our data confirm that carnosinase activity and expression is nearly absent from skeletal muscle. The stability of supplementation-induced changes in muscle carnosine content for weeks/months is in sharp contrast to short half-life of carnosine in human plasma, which is hydrolyzed by serum carnosinase within hours (10) . Some animal experiments have suggested that carnosine is actively secreted by skeletal muscle during exercise (23) , and possibly in a paracrine/endocrine fashion can contribute to, e.g., the hemodynamic adaptation to exercise (27) . However, considerable net release of carnosine during exercise is contradictory to the high stability of muscle carnosine content in our active study population. This is further supported by the lack of correlation between physical activity level and washout rate (r ϭ Ϫ0.331; P ϭ 0.469) in our subjects.
Although we only have limited measurements during the postsupplementation period, the washout seems to follow a linear rather than exponential decay, which is somewhat unusual for biological systems. It could be hypothesized that the linear rather than exponential decay of carnosine from the In the present experiment, the magnitude of increase in muscle carnosine content following supplementation was 23-39% (ϳ2 mM). This is somewhat lower than most (6, 13, 14) but not all (19) previous studies, which may relate to the lower dose of ␤-alanine (4.8 g instead of 6.4 g in Ref.
14) and the physical activity level (sprinters in training season in Ref. 6 ). The rate of carnosine elimination was on average 0.21 mM/wk and appears to be linear. Individual data ( Fig. 2A) show that the percent increase in muscle carnosine content varies largely between subjects (between ϩ2% and ϩ69%). When in a post hoc analysis the subjects with the highest increase in muscle carnosine content (high responders; ϩ55%) are grouped, it appears that with a relative decline of 3.5%/wk, it takes almost 15 wk to complete washout, whereas in the low responders, the initial 15% increase disappeared at a rate of 2.5%/wk and was returned to baseline within 6 wk (Fig. 2B) . Even larger elevations in muscle carnosine content of ϩ80%, as observed in Ref.
14, would accordingly require a washout period in the range of 20 wk. To our knowledge, carnosine is the first metabolite to be described with such a slow decay in muscle. This may change the traditional view of exercise physiologists on safe washout periods in crossover supplementation studies. When browsing the literature, it becomes clear that 1-4 wk of washout is usually adopted as a sufficient washout period in various studies. For creatine, the 4 wk have been generally accepted based on the available evidence (Fig. 3) , but for other supplements washout has never been determined. The present study emphasizes the importance of experimentally determining metabolite washout periods before crossover studies can be performed. Additionally, these washout periods can be much longer than currently believed (months rather than weeks).
The slow elimination of carnosine from the muscle suggests a high stability of this metabolite's concentration. If carnosine is indeed a muscle characteristic with little dynamics, then muscle carnosine content should remain relatively constant over a long period in the placebo group. Indeed, as shown in Table 1 , the four measurements over the 15-wk period display a relatively low CV of 9.8% in soleus, 13.8% in tibialis anterior, and 14.2% in gastrocnemius. The methodological variation of the MRS has been previously determined to be 4.3% and 7.6% for soleus and gastrocnemius, respectively, when subjects are measured twice on the same day (25) . Thus the biological variation of muscle carnosine content over a 15-wk period is as low as ϳ6%. In the present study population, we did not observe a positive correlation between dietary ␤-alanine ingestion and baseline carnosine content, suggesting that within certain limits diet is not greatly affecting muscle carnosine content. The constancy of muscle carnosine content over time opens perspectives for the use of carnosine quantification as a possible tool in the noninvasive assessment of muscle fiber type composition, muscle buffer capacity, and eventually talent identification.
An additional goal of the present study was to compare the responsiveness of different muscle types to carnosine loading. Carnosine is believed to be important for pH homeostasis (1, 4) and is therefore across species (including humans) more abundantly found in fast-twitch type muscles (7, 8, 14) . This is also confirmed in the present study as baseline carnosine content is significantly higher (ϳ20%) in the fast-twitch gastrocnemius than the more slow-twitch tibialis anterior and soleus. It could be hypothesized that fast-twitch muscles have higher carnosine content because they display a higher expression of transporters for ␤-alanine (2) or carnosine (3) or of carnosine synthase (15, 32) . If this were the case, then a larger effect of ␤-alanine supplementation would be expected in gastrocnemius than in the other muscles. However, the relative increase was even significantly higher in the soleus than in the other two muscles. Thus the above hypothesis is not supported. Our findings support earlier evidence showing that within the same muscle (human vastus lateralis), type I and type II fibers respond equally well to ␤-alanine supplementation (14) . Rodent studies have reported larger increases in soleus carnosine content compared with more fast-twitch muscle types (21) . It therefore remains to be determined why baseline (steady state) carnosine content is higher in fast-twitch muscles. This and other studies at least suggest that ␤-alanine availability is not a key factor herein.
It can be concluded from the present study that in both slow-twitch and fast-twitch human skeletal muscle carnosine appears to be a highly stable metabolite. This is supported by the slow and linear washout profile following cessation of ␤-alanine supplementation and the relatively constant muscle carnosine content in the placebo group over several months.
